Safety, efficacy, and immunogenicity of the NVX-CoV2373 vaccine

• Egile Nagusiak: Eddie Underwood (Egilea), Lisa M. Dunkle (Egilea), Shabir A. Madhi (Egilea), Cynthia L. Gay (Egilea), Paul T. Heath (Egilea), Karen L. Kotloff (Egilea), Katherine Smith (Egilea), Gordon Chau (Egilea), Shirley Galbiati (Egilea), Alice McGarry (Egilea), Wayne Woo (Egilea), Iksung Cho (Egilea), Katia Alves (Egilea), Germán Áñez (Egilea), Chijioke Bennett (Egilea), Vivek Shinde (Egilea), Louis Fries (Egilea), Raburn M. Mallory (Egilea), Gregory M. Glenn (Egilea), Seth Toback (Egilea)
• Formatua: Liburua
• Argitaratua: Taylor & Francis Group, 2023-12-01T00:00:00Z.
• Gaiak: article
• Sarrera elektronikoa: Connect to this object online.

Introduction The coronavirus disease 2019 (COVID-19) pandemic, caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), has resulted in significant morbidity and mortality worldwide. As SARS-CoV-2 moves into endemic status, vaccination remains a key element in protecting the health of...